Compare Biocon Ltd with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs VENUS REMEDIES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON VENUS REMEDIES BIOCON /
VENUS REMEDIES
 
P/E (TTM) x 26.7 -2.5 - View Chart
P/BV x 3.4 0.2 2,091.4% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    VENUS REMEDIES
EQUITY SHARE DATA
    BIOCON
Mar-19
VENUS REMEDIES
Mar-18
BIOCON /
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs707126 561.8%   
Low Rs55461 906.4%   
Sales per share (Unadj.) Rs91.9301.8 30.5%  
Earnings per share (Unadj.) Rs16.7-24.9 -67.2%  
Cash flow per share (Unadj.) Rs24.22.5 950.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.6293.3 34.7%  
Shares outstanding (eoy) m600.0012.34 4,862.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.90.3 2,214.5%   
Avg P/E ratio x37.7-3.8 -1,003.7%  
P/CF ratio (eoy) x26.136.7 71.0%  
Price / Book Value ratio x6.20.3 1,946.1%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,3301,154 32,790.2%   
No. of employees `0006.10.9 662.8%   
Total wages/salary Rs m11,653393 2,964.4%   
Avg. sales/employee Rs Th8,994.34,026.1 223.4%   
Avg. wages/employee Rs Th1,900.7425.0 447.2%   
Avg. net profit/employee Rs Th1,635.3-331.8 -492.9%   
INCOME DATA
Net Sales Rs m55,1443,724 1,480.7%  
Other income Rs m1,44423 6,417.8%   
Total revenues Rs m56,5883,747 1,510.4%   
Gross profit Rs m15,883395 4,023.0%  
Depreciation Rs m4,478338 1,323.7%   
Interest Rs m709354 200.1%   
Profit before tax Rs m12,140-275 -4,409.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,12332 6,718.4%   
Profit after tax Rs m10,026-307 -3,266.9%  
Gross profit margin %28.810.6 271.7%  
Effective tax rate %17.5-11.5 -152.4%   
Net profit margin %18.2-8.2 -220.6%  
BALANCE SHEET DATA
Current assets Rs m48,2282,638 1,828.4%   
Current liabilities Rs m30,3762,305 1,318.0%   
Net working cap to sales %32.48.9 362.0%  
Current ratio x1.61.1 138.7%  
Inventory Days Days68135 50.4%  
Debtors Days Days8646 184.6%  
Net fixed assets Rs m64,1304,871 1,316.6%   
Share capital Rs m3,000123 2,431.1%   
"Free" reserves Rs m57,9803,496 1,658.6%   
Net worth Rs m60,9803,619 1,684.9%   
Long term debt Rs m15,7661,374 1,147.1%   
Total assets Rs m121,9247,509 1,623.8%  
Interest coverage x18.10.2 8,127.7%   
Debt to equity ratio x0.30.4 68.1%  
Sales to assets ratio x0.50.5 91.2%   
Return on assets %8.80.6 1,394.7%  
Return on equity %16.4-8.5 -193.9%  
Return on capital %16.81.6 1,059.0%  
Exports to sales %28.10-   
Imports to sales %18.913.9 136.0%   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399517 2,013.2%   
Fx inflow Rs m15,5060-   
Fx outflow Rs m10,399517 2,013.4%   
Net fx Rs m5,107-517 -988.8%   
CASH FLOW
From Operations Rs m11,546514 2,244.6%  
From Investments Rs m-7,138-123 5,798.5%  
From Financial Activity Rs m-2,417-387 624.4%  
Net Cashflow Rs m2,1034 50,071.4%  

Share Holding

Indian Promoters % 40.4 32.9 123.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,666.7%  
FIIs % 10.7 0.6 1,844.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 66.4 30.0%  
Shareholders   109,995 20,121 546.7%  
Pledged promoter(s) holding % 0.0 36.4 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FDC LTD.  UNICHEM LAB  WYETH LTD  ELDER PHARMA  ALEMBIC LTD  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 260 Points Lower; Finance and Banking Stocks Witness Huge Selling(Closing)

Indian share markets witnessed negative trading activity today and ended their trading session lower.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

Covid-19 Offers a Rare Opportunity to Own This Brand Leader(Profit Hunter)

May 12, 2020

Covid-19 has compounded uncertainties in investing but this smallcap company is strong enough to survive and even emerge stronger.

Of India's 20 Trillion Stimulus Package and the Swoosh Index for a Swoosh Recovery(Profit Hunter)

May 13, 2020

For India's rapid economic recovery, hopping on to the Swoosh index is a must.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 22, 2020 (Close)

TRACK BIOCON

BIOCON - ALEMBIC PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS